Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Ascidian Therapeutics

Company Type: Therapeutic development

Main focus: Developing RNA therapeutics to treat diseases

Company stage: Clinical

Diseases: Stargardt disease and and other ABCA4 retinopathies, as well as neuro- and neuromuscular diseases

Genome-editing tool: RNA exon editing

Funding stage: Series A

Location: Boston, Massachusetts, USA

Website: https://ascidian-tx.com/

Pipeline: https://ascidian-tx.com/programs/

Partners:

Ascidian Therapeutics is a clinical-stage company that aims to develop RNA medicines to treat various genetic diseases. The company's RNA exon-editing platform provides precise post-transcriptional editing of mRNA transcripts to restore full-length, functional proteins. Ascidian is currently initiating a clinical trial, called STELLAR, to evaluate the exon-editing candidate ACDN-01 in adults with Stargardt disease and other ABCA4 retinopathies.

Tags

HashtagAscidian Therapeutics

Company: Ascidian Therapeutics
close
Search CRISPR Medicine